No, CBD is not addictive: the World Health Organization’s 2017 review found no effects indicative of abuse or dependence potential, because cannabidiol does not bind CB1 receptors, produce euphoria, or trigger the dopamine reward loop that drives craving.
CBD is the second most prevalent compound in cannabis, and it influences endocannabinoid receptors without binding them the way THC does.
Key Takeaways
- CBD is not addictive. The World Health Organization’s 2017 report confirms that CBD, in its pure state, shows no abuse or dependence potential
- 79.2% of patients, 57 of 72, showed improvement in anxiety within the first month of CBD use in a 2019 retrospective case series. The authors note the open-label design and absence of a control group limit what can be attributed to CBD alone
- No withdrawal symptoms occur when stopping CBD, unlike THC or other substances that affect dopamine levels
- Cannabidiol is not an approved addiction treatment. Early studies report reduced craving for tobacco and opioids, but the FDA has approved cannabidiol only for three seizure disorders: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
- Prescription cannabidiol cut seizure frequency by roughly two-thirds in a 2018 open-label study of 132 patients with treatment-resistant epilepsy, at medically supervised doses of 5 to 50 mg/kg/day
Can You Get Addicted to CBD?
No. The World Health Organization confirmed in 2017 that CBD shows “no effects indicative of any abuse or dependence potential”, and neither physical nor psychological dependence develops from it.
Two types of dependence matter here. Physical dependence means the body needs a substance to function normally, and cannabidiol does not produce it: no withdrawal syndrome develops even after prolonged daily use. That separates cannabidiol entirely from opioids, benzodiazepines and alcohol.
Psychological dependence means compulsive cravings driven by dopamine reward loops. CBD does not activate those loops and does not bind to CB1 receptors the way THC does, so no euphoria, no craving cycle and no psychological dependence follow.
CBD is not a controlled substance under federal law. The 2018 Farm Bill removed hemp-derived CBD from the Controlled Substances Act, and the FDA’s approval of Epidiolex, a prescription CBD medication, reinforces that cannabidiol does not meet the threshold for scheduling.
Morgan and colleagues reported that cannabidiol reduced cigarette consumption in a small pilot trial of tobacco smokers, and comparable early work reports reduced opioid craving. Both findings are preliminary rather than established, which makes cannabidiol a research subject rather than an addictive substance.
Is CBD Oil Addictive?
No. CBD oil carries the same absence of dependence potential as every other cannabidiol product, because the delivery method does not change cannabidiol’s chemical structure, and oil, tinctures and topicals behave identically.
Quality matters when selecting CBD oil. Full-spectrum products contain trace THC. Broad-spectrum and isolate options contain none. Third-party lab certificates verify which is which.
People with chronic conditions use CBD oil daily, and daily use does not indicate addiction or dependence. Medical supervision keeps the dose appropriate to the therapeutic goal.
Are CBD Gummies Addictive?
No. CBD gummies are not addictive despite their taste, because the cannabidiol content determines the effect rather than the delivery format, and sweet flavoring creates no dependency of its own.
Gummies provide consistent dosing per piece, and most contain 10 to 25mg of CBD each. That consistency makes them popular for anxiety and sleep.
Behavioral patterns around gummy use differ from addiction. Taking CBD gummies daily for a medical purpose is not habit formation, and the body develops no craving for cannabidiol.
Does CBD Have Withdrawal Symptoms?
No. CBD produces no withdrawal symptoms on discontinuation, because regular use creates no physical dependence, and stopping abruptly is medically safe in a way that stopping benzodiazepines or opioids is not.
The body does not require continued dosing to function normally. Unlike benzodiazepines or opioids, cannabidiol has no withdrawal syndrome to manage.
Some users report symptoms returning after they stop, and those are the original condition reappearing rather than withdrawal. Anxiety or pain that comes back after stopping CBD reflects the baseline condition, not a new dependence.
What Is the Difference Between CBD and THC?
THC activates CB1 receptors and produces euphoria, physical dependence and positive drug tests; CBD does not bind those receptors directly, produces no high, and the WHO review found no dependence potential for it.
THC and CBD share similar chemical structures and produce opposite effects. CBD and THC differ across 4 dimensions:
- Psychoactive Effects: THC produces a high; CBD does not
- Legal Status: Hemp-derived CBD is federally legal; THC remains Schedule I
- Addiction Potential: THC produces dependence; the WHO review found no abuse or dependence potential for cannabidiol
- Drug Testing: THC triggers positive tests; pure CBD does not
Hemp is not addictive either. Federal law defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. At that concentration THC does not produce intoxication at normal serving sizes, and cannabidiol itself shows no dependence potential. Concentrated and mislabeled hemp-derived products are a separate concern, because nothing verifies their THC content against the label.
THC is the driving force behind marijuana use disorder and cannabis use disorder (CUD), a recognized DSM-5-TR diagnosis tied to compulsive, THC-driven use. CBD is not implicated in either condition.
The relationship in fact runs the other way. Cannabidiol counteracts some THC effects, reducing anxiety, paranoia and the reinforcing pull of intoxication, which makes it an active area of research in cannabis use disorder treatment.
How Does CBD Make You Feel?
CBD produces calm and reduced physical tension within 30 to 60 minutes without intoxication, and it leaves perception, thinking and the ability to drive or work unchanged.
Most users report feeling calmer and more relaxed. Anxiety scores improved for 57 of 72 patients, or 79.2%, within the first month in Shannon and colleagues’ 2019 case series. The series had no control group, so the improvement cannot be attributed to cannabidiol alone.
You will not experience altered perception or impaired thinking. CBD does not impair the ability to drive or work, and cognitive function remains normal. CBD produces 5 common sensations:
- Reduced anxiety or worry
- Improved sleep quality
- Decreased pain or inflammation
- Sharpened focus without jitters
- Relaxed muscles
Individual responses vary with dosage and product type. Start at 10 to 20mg to assess your reaction.
What Are the Side Effects of CBD?
CBD produces few side effects at typical consumer doses, and the ones it produces, tiredness, appetite change, diarrhea, dry mouth and dizziness, are temporary and concentrated at doses above 300mg daily.
The National Center for Complementary and Integrative Health, part of the National Institutes of Health, records few adverse reactions at typical consumer doses. CBD produces 5 possible side effects:
- Tiredness or drowsiness
- Changes in appetite
- Diarrhea (with high doses)
- Dry mouth
- Dizziness
Doses of 25 to 100mg rarely produce problems, and side effects at any dose do not indicate addiction or dependence.
CBD interacts with medications metabolized by the liver’s CYP450 enzymes. Cannabidiol competes with blood thinners, antidepressants and seizure medications for those enzymes, which changes how much of each drug reaches the blood. Consult a doctor before combining CBD with prescriptions.
Is CBD Habit Forming?
No. CBD forms no habits and no compulsive use patterns, because it leaves the brain’s reward pathways untouched, produces no euphoria, and builds no tolerance requiring progressively higher doses.
Psychological dependence requires a dopamine-driven reward loop, and cannabidiol does not trigger one. CBD produces no euphoria, reinforces no craving cycle, and creates none of the behavioral patterns that define dependence.
Tolerance does not build either. Unlike opioids, alcohol or caffeine, cannabidiol does not require progressively higher doses to maintain its effects, and receptors do not desensitize to it over time.
Reports of the opposite effect, called CBD reverse tolerance, describe regular users needing less cannabidiol over time rather than more. The proposed mechanism is CBD’s upregulation of endocannabinoid receptors.
That absence of tolerance is what separates therapeutic daily use from addictive behavior. Taking CBD consistently for pain, anxiety or sleep follows a medical use pattern, and regular use for a medical condition is treatment rather than habit formation.
What Are the Long-Term Effects of CBD on Your Body?
Long-term cannabidiol evidence comes mainly from open-label epilepsy studies, where benefits held for up to 48 weeks without dose increases, and long-term data outside epilepsy remain limited.
The epilepsy studies do not establish that tolerance never develops. CBD shows 3 documented long-term effects:
- Anti-Anxiety Effects: A 2019 retrospective case series of 72 patients recorded improvement in anxiety for 79.2%, or 57 of 72, within one month. Benefits were sustained throughout the study period without dosage increases.
- Anti-Seizure Properties: Szaflarski and colleagues gave pharmaceutical cannabidiol to 72 children and 60 adults with treatment-resistant epilepsy in a 2018 open-label add-on study. Two-week seizure frequency fell from a mean of 144.4 at entry to 52.2 by week 12 and held stable through week 48, while seizure severity scores fell from 80.7 to 39.2. Doses ran from 5 to 50 mg/kg/day under medical supervision, far above the amounts in consumer CBD products.
- Pain Management: Boyaji and colleagues describe cannabis-based medicines as possible adjuncts to opioid analgesics for chronic pain rather than established replacements.
Long-term use does not damage organs or create dependency, and the body maintains its response to cannabidiol over time.
Is Cannabidiol Addictive Compared to Other Substances?
Cannabidiol ranks among the least addictive substances studied: it creates no physical dependence, where nicotine, alcohol and opioids all do, and caffeine produces a documented withdrawal syndrome that cannabidiol does not.
Unlike nicotine, alcohol or opioids, cannabidiol creates no physical dependence, and brain chemistry remains balanced during use. Caffeine produces a documented withdrawal syndrome and cannabidiol produces none, which is the sharpest available contrast.
Researchers are studying cannabidiol in alcohol, cocaine and opioid use disorder, and the human evidence remains early. Cannabidiol is not an approved treatment for any of them, and outpatient programs treat those disorders with established therapies.
Can You Be Addicted to Hemp?
No. Hemp products containing CBD are not addictive, because federal law caps hemp at 0.3% delta-9 THC on a dry weight basis and cannabidiol itself shows no abuse potential.
Hemp-derived CBD oil, gummies and topicals produce no dependence. Product quality is the real variable, because nothing verifies the THC content of an unregulated product against its label. The plant source does not change cannabidiol’s chemical properties, and federal legalization reflects hemp’s safety profile.
Industrial hemp contains cannabinoids beyond CBD. CBG, CBN and CBC all demonstrate therapeutic potential, and none of the three creates addiction or dependence.
Is Vaping CBD Addictive?
No. Vaping cannabidiol carries no more addiction risk than any other delivery method, because inhalation changes the speed of onset rather than cannabidiol’s chemical properties, and pure CBD vape products contain no nicotine.
Nicotine vapes are highly addictive; CBD vapes carry no nicotine and no addictive substance of any kind. That distinction is the one that matters.
Vaping delivers relief for acute symptoms within minutes, against 30 to 60 minutes for edibles. That speed does not indicate addiction potential.
Is CBD Addiction the Same as Cannabis Use Disorder?
No. Cannabis use disorder involves THC-containing marijuana rather than cannabidiol, and Budney and colleagues record dependency developing in approximately 9% of marijuana users, which traces to THC’s psychoactive effects.
Marijuana’s THC drives the compulsive use pattern that defines the disorder, and cannabidiol has no role in it. Budney and colleagues set out the dependence and treatment picture for marijuana. Cannabidiol is under study as a treatment for cannabis use disorder, where early trials record reduced marijuana cravings and withdrawal symptoms. That application is the opposite of an addiction profile.
Cannabis use disorder presents with 5 signs:
- Inability to reduce marijuana use despite wanting to
- Excessive time spent obtaining or using cannabis
- Cravings for marijuana’s psychoactive effects
- Continued use despite negative consequences
- Withdrawal symptoms when stopping
Pure CBD products do not produce these patterns. Check the THC content of any cannabis product that produces them.
When Does CBD Use Signal Another Problem?
CBD use signals another problem when a person reaches for it to avoid emotional pain, when it replaces healthy coping, or when it substitutes for treatment of an unaddressed mental health condition.
Cannabidiol itself is not addictive, and the reason a person reaches for it is the thing worth examining. Using any substance to avoid emotional pain deserves attention, and self-medication differs from addiction while still requiring support. 5 patterns warrant professional help:
- Using CBD to escape difficult emotions daily
- Substituting CBD for healthy coping mechanisms
- Avoiding treatment for a mental health condition
- Taking CBD products that contain unknown THC levels
- Combining CBD with addictive substances
CBD works best alongside comprehensive mental health care. Addiction therapy, medication and lifestyle changes create lasting wellness, and cannabidiol supplements professional treatment rather than replacing it.
What Are the Benefits of CBD in Addiction Recovery?
Chye and colleagues describe early promise for cannabidiol in supporting recovery, including potential benefits for alcohol, opioid and stimulant use disorder, where it addresses cravings and anxiety at once.
The review covers the endocannabinoid system and cannabidiol in substance use disorder, and its conclusions are preliminary rather than established. Cannabidiol holds no FDA approval for any substance use disorder, including stimulant addiction. Research covers 4 recovery applications:
- Opioid Withdrawal: Cannabidiol reduces acute withdrawal symptoms and cravings in early trials
- Alcohol Recovery: Turna and colleagues rate the preclinical evidence promising and the human evidence insufficient
- Tobacco Cessation: Morgan and colleagues recorded reduced cigarette consumption in a small pilot trial
- Anxiety Management: Cannabidiol addresses co-occurring mental health conditions alongside the substance use disorder
Cannabidiol is non-intoxicating, which makes it acceptable during recovery. Whether a program permits CBD is a program-by-program policy, so discuss cannabidiol with your treatment team before starting it.
How Do You Choose a Safe CBD Product?
Choose a CBD product with a third-party certificate of analysis confirming THC below 0.3%, CO2 extraction, a domestic organic hemp source, a declared spectrum type, and per-serving CBD and THC content on the label.
Third-party lab testing verifies cannabinoid content and purity. A certificate of analysis confirms THC levels below 0.3%. Check 5 things on any CBD product:
- COA (Certificate of Analysis): Independent lab verification
- Extraction Method: CO2 extraction produces the cleanest products
- Hemp Source: Organically grown domestic hemp
- Product Type: Full-spectrum, broad-spectrum, or isolate
- Transparent Labeling: Clear CBD and THC content per serving
Avoid products making medical claims beyond FDA approval. Cannabidiol holds FDA approval only for three seizure disorders under prescription as Epidiolex, and every other benefit awaits further research.
Is CBD Legal and Safe?
The 2018 Farm Bill legalized hemp-derived CBD federally at no more than 0.3% THC, and the World Health Organization’s 2017 review judged cannabidiol generally well tolerated with a good safety profile.
That safety judgment sits alongside the prescription label’s documented risks: dose-related liver enzyme elevations, sedation, and a standing instruction to monitor for suicidal behavior and ideation. Serious effects are uncommon at the doses in consumer products, and they are not absent: they concentrate at high doses and in combination with other medicines.
State laws vary, and most states permit the sale of legal CBD. FDA oversight remains limited for CBD supplements, which poses quality-control challenges in the market. Reputable brands offering third-party testing are the practical safeguard.
What Is a Safe CBD Dosage?
No standard CBD dosage exists for all conditions, and most therapeutic effects occur between 25 and 100mg daily, starting at 10 to 20mg and increasing gradually under medical supervision.
Dosage varies with the condition. The literature reports 4 general ranges:
- Anxiety: 25-75mg daily
- Sleep: 40-160mg before bed
- Pain: 40-100mg daily, divided doses
- Inflammation: 50-150mg daily
Higher doses of CBD, above 300mg, are under study for specific conditions. McGuire and colleagues, in a multicenter randomized controlled trial, tested cannabidiol at 1,000 mg/day as a well-tolerated adjunctive treatment for schizophrenia, particularly reducing positive psychotic symptoms.
Medical supervision keeps the dose appropriate. Do not exceed recommended amounts without professional guidance.
Frequently Asked Questions
Does CBD show up on drug tests?
No. Pure CBD does not trigger positive drug tests. Tests screen for THC, not cannabidiol. However, full-spectrum products with trace THC may cause false positives. Use THC-free isolate products if drug testing is a concern.
Can you overdose on CBD?
Fatal overdose on cannabidiol alone has not been documented, but cannabidiol is not free of serious risk. The FDA label for prescription cannabidiol (Epidiolex) directs prescribers to measure liver transaminases and bilirubin before treatment because cannabidiol can cause hepatocellular injury. That risk rises at higher doses and when cannabidiol is combined with valproate. The same label lists somnolence and sedation, and instructs prescribers to monitor for suicidal behavior and ideation. High doses commonly cause diarrhea, reduced appetite, and sedation. Anyone taking other prescription medicine should review cannabidiol with a prescriber before starting it.
Is CBD addictive like marijuana?
No. Marijuana’s addictive potential comes from THC, not CBD. Hemp-derived CBD products contain no more than 0.3% delta-9 THC under the federal definition, and cannabidiol itself does not produce dependence.
How long does CBD stay in your system?
A single dose of cannabidiol generally clears within two to five days, but heavy or prolonged use extends that window because cannabidiol is fat-soluble and distributes into adipose tissue. Dose, frequency, and metabolism all affect elimination. Stopping cannabidiol does not require medically supervised detoxification.
Can CBD help with alcohol addiction?
Turna and colleagues, in a systematic review of cannabidiol as a candidate treatment for alcohol use disorder, describe the preclinical evidence as promising and the human evidence as not yet sufficient. CBD should supplement, not replace, professional addiction care.
Medical Disclaimer: This information is educational and not medical advice. Consult healthcare providers before starting CBD, especially with existing conditions or medications. Riverside Recovery of Tampa provides addiction treatment services only; we don’t prescribe or recommend CBD for medical conditions.
References
- Patel P, Curry S. Cannabidiol (CBD) in clinical care. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2024 May 7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556048/
- World Health Organization. Cannabidiol (CBD): critical review report. Expert Committee on Drug Dependence, Fortieth Meeting, Geneva, Switzerland, 6-10 November 2017. Geneva: World Health Organization; 2018. Available from: https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf
- Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18-041. doi:10.7812/TPP/18-041. PubMed PMID: 30624194; PubMed Central PMCID: PMC6326553.
- Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013 Sep;38(9):2433-6. doi:10.1016/j.addbeh.2013.03.011. Epub 2013 Apr 1. PubMed PMID: 23685330.
- US Drug Enforcement Administration. Drug scheduling. Available from: https://www.dea.gov/drug-information/drug-scheduling [Accessed 2026 Feb 11].
- National Institutes of Health, National Center for Complementary and Integrative Health. Cannabis (marijuana) and cannabinoids: what you need to know. Bethesda (MD): NIH; updated 2023 Aug. Available from: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know [Accessed 2026 Feb 11].
- Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007 Dec;4(1):4-16. doi:10.1151/ascp07414. PubMed PMID: 18292704; PubMed Central PMCID: PMC2797098.
- Boyaji S, Merkow J, Elman RN, Kaye AD, Yong RJ, Urman RD. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020 Feb 10;24(2):4. doi:10.1007/s11916-020-0835-4.
- McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi:10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. PubMed PMID: 29241357.
- Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res. 2019 Apr;43(4):550-563. doi:10.1111/acer.13964. Epub 2019 Feb 19. PubMed PMID: 30698831; PubMed Central PMCID: PMC6910215.
- Chye Y, Christensen E, Solowij N, Yucel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. 2019 Feb 19;10:63. doi:10.3389/fpsyt.2019.00063.
- Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA; UAB CBD Program. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016 Oct;57(10):1617-1624. doi:10.1111/epi.13499. Epub 2016 Aug 25. PubMed PMID: 27558841.